Coregistered whole body magnetic resonance imaging‐positron emission tomography (MRI‐PET) versus PET‐computed tomography plus brain MRI in staging resectable lung cancer

Abstract

BACKGROUND:The objective of this study was to assess whether coregistered whole brain (WB) magnetic resonance imaging-positron emission tomography (MRI-PET) would increase the number of correctly upstaged patients compared with WB PET-computed tomography (PET-CT) plus dedicated brain MRI in patients with nonsmall cell lung cancer (NSCLC). METHODS: From January 2010 through November 2011, patients with NSCLC who had resectable disease based on conventional staging were assigned randomly either to coregistered MRI-PET or WB PET-CT plus brain MRI (ClinicalTrials.gov trial NCT01065415). The primary endpoint was correct upstaging (the identification of lesions with higher tumor, lymph node, or metastasis classification, verified with biopsy or other diagnostic test) to have the advantage of avoiding unnecessary thoracotomy, to determine appropriate treatment, and to accurately predict patient prognosis. The secondary endpoints were over staging and under staging compared with pathologic staging. RESULTS: Lung cancer was correctly upstaged in 37 of 143 patients (25.9%) in the MRI-PET group and in 26 of 120 patients (21.7%) in the PET-CT plus brain MRI group (4.2% difference; 95% confidence interval, À6.1% to 14.5%; P ¼ .426). Lung cancer was over staged in 26 of 143 patients (18.2%) in the MRI-PET group and in 7 of 120 patients (5.8%) in the PET-CT plus brain MRI group (12.4% difference; 95% confidence interval, 4.8%-20%; P ¼ .003), whereas lung cancer was under staged in 18 of 143 patients (12.6%) and in 28 of 120 patients (23.3%), respectively (À10.7% difference; 95% confidence interval, À20.1% to À1.4%; P ¼ .022). CONCLUSIONS: Although both staging tools allowed greater than 20% correct upstaging compared with conventional staging methods, coregistered MRI-PET did not appear to help identify significantly more correctly upstaged patients than PET-CT plus brain MRI in patients with NSCLC. Cancer INTRODUCTIONIn an effort to improve diagnostic accuracy and to compensate for the drawbacks of individual imaging modalities, alternative hardware-based and software-based approaches to postprocessing alignment of each imaging device involve the fusion of different imaging techniques in a single scanner.1,2 This and other similar efforts have been directed at synergistic effect of individual performance of computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI) beyond an ordinary additive effect of those individual components.One of the most important indications for whole body (WB) imaging is the detection of metastases. PET-CT is the most popular imaging device for metastasis workup. 3,4 With the development of fast MRI techniques (fast, T2-weighted [T2W] spin-echo and 3-dimensional, gradient-echo sequences) and a rolling table platform, Currently, WB MRI also is being used for metastatic workup.

Can Digital Games Be a Way of Improving the Neuroplasticity in Stroke Damage? Can the Adult Brain Grow New Cells or Rewire Itself in Response to a New Experience?

“…Studies have shown through the used PET, and MRI brain scanning technology, those new neural cells are generated through life as well as new neural pathways [17] [18]. So, old brains are capable of creating measurable changes in brain organization.…”

PET/MRI in Lung Cancer

“…In this study, lung cancer was correctly upstaged 25.9% (37 of 143 patients) in the PET/MRI group and 21.7% (26 of 120 patients) in the PET/CT plus brain MRI group. 69 Coregistered PET/MRI did not appear to help identify significantly more correctly upstaged patients than PET/CT plus brain MRI in patients with NSCLC. However, PET/CT plus brain MRI can improve the detection of brain metastases (32 of 442 patients; 7%) in comparison with PET/CT only.…”

Positron Emission Tomography/Magnetic Resonance Imaging Practices in Oncological Imaging

“…FDG PET/BT'nin lenf nodu, kemik ve yumuşak doku metastazlarının saptanmasındaki yüksek doğruluk oranı ile klinik uygulanabilirlik kolaylığı, bu yöntemi akciğer kanseri olgularının değerlendirilmesinde ön planda tutmaktadır. Tüm vücut PET/MR'ın tüm vücut PET/BT + beyin MR görüntülemesi ile karşılaştırıldığı bir çalışmada iki görüntüleme protokolü arasında hasta evrelemesinde belirgin farklılık olmadığı belirtilmektedir (78).…”